A183490 Stock Overview
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enzychem Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,728.00 |
| 52 Week High | ₩2,080.00 |
| 52 Week Low | ₩1,110.00 |
| Beta | 1.46 |
| 1 Month Change | -2.87% |
| 3 Month Change | -4.32% |
| 1 Year Change | -10.09% |
| 3 Year Change | -93.25% |
| 5 Year Change | -88.08% |
| Change since IPO | -67.45% |
Recent News & Updates
Shareholder Returns
| A183490 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.2% | -5.0% | -4.3% |
| 1Y | -10.1% | -1.4% | -1.0% |
Return vs Industry: A183490 underperformed the KR Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: A183490 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A183490 volatility | |
|---|---|
| A183490 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A183490 has not had significant price volatility in the past 3 months.
Volatility Over Time: A183490's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 113 | Ki-Young Sohn | www.enzychem.com |
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
Enzychem Lifesciences Corporation Fundamentals Summary
| A183490 fundamental statistics | |
|---|---|
| Market cap | ₩146.99b |
| Earnings (TTM) | -₩9.33b |
| Revenue (TTM) | ₩76.04b |
1.9x
P/S Ratio-15.8x
P/E RatioIs A183490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A183490 income statement (TTM) | |
|---|---|
| Revenue | ₩76.04b |
| Cost of Revenue | ₩71.69b |
| Gross Profit | ₩4.35b |
| Other Expenses | ₩13.67b |
| Earnings | -₩9.33b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -109.64 |
| Gross Margin | 5.72% |
| Net Profit Margin | -12.27% |
| Debt/Equity Ratio | 2.3% |
How did A183490 perform over the long term?
See historical performance and comparison